Skip to main content
main-content

15-06-2022 | EULAR 2022 | Conference coverage | Video

BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice?

share
SHARE

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities (3:19).

EULAR 2022 Congress coverage

Access the latest news and expert insight from the EULAR 2022 Congress.

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.